Akebia Therapeutics Inc. (AKBA)
| Bid | 1.87 |
| Market Cap | 500.26M |
| Revenue (ttm) | 198.36M |
| Net Income (ttm) | -85.96M |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -5.8 |
| Forward PE | -16.96 |
| Analyst | Buy |
| Ask | 1.95 |
| Volume | 3,381,066 |
| Avg. Volume (20D) | 3,454,698 |
| Open | 1.94 |
| Previous Close | 1.93 |
| Day's Range | 1.88 - 1.94 |
| 52-Week Range | 0.80 - 2.89 |
| Beta | 0.94 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...
Analyst Forecast
According to 2 analyst ratings, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is $6.75, which is an increase of 252.48% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call TranscriptAkebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Co...
1 month ago · seekingalpha.com
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues DeclineAkebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's sig...
